Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 12/2006

01-12-2006 | Original Article

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

Authors: Paal F. Brunsvig, Steinar Aamdal, Marianne K. Gjertsen, Gunnar Kvalheim, Carrie J. Markowski-Grimsrud, Ingunn Sve, Marianne Dyrhaug, Sissel Trachsel, Mona Møller, Jon A. Eriksen, Gustav Gaudernack

Published in: Cancer Immunology, Immunotherapy | Issue 12/2006

Login to get access

Abstract

Purpose: A phase I/II study was conducted to investigate the safety, tolerability and clinical response to vaccination with a combination of telomerase peptides GV1001 (hTERT: 611–626) and HR2822 (hTERT: 540–548) in patients with non-small cell lung cancer. Experimental design: Twenty-six patients with non-small cell lung cancer received intradermal administrations of either 60 nmole (112 μg) or 300 nmole (560 μg) GV1001 in combination with 60 nM (68.4 μg) HR2822 and granulocyte macrophage-colony stimulating factor. The treatment period was 10 weeks. Booster vaccinations with 300 nM GV1001 were offered as follow-up. Monitoring of blood samples, clinical examination and radiological staging were performed regularly. Immune responses were measured as delayed-type hypersensitivity skin reaction and in vitro T cell proliferation. Bone marrow function was monitored in long time survivors. Results: The treatment was well tolerated with minor side effects. No bone marrow toxicities were observed in long time survivors with immune responses. Immune responses against GV1001 were detected in 11 of 24 evaluable patients during the primary regimen and in additional two patients following booster injections. Two patients responded to HR2822. Cloned GV1001-specific CD4+ T cells displayed a Th1 cytokine profile and recognized autologous antigen presenting cells pulsed with recombinant telomerase protein. A complete tumor response was observed in one patient who developed GV1001-specific cytotoxic T cells that could be cloned from peripheral blood. Conclusion: The results demonstrate that GV1001 and HR2822 are immunogenic and safe to use in patients with NSCLC. Induction of GV1001-specific immune responses may result in objective tumor responses. Based on these initial encouraging results, further clinical studies of GV1001 in NSCLC patients are warranted.

Footnotes
1

In the study protocol GV1001 is referred to as HR2802

 
Literature
  1. Shepherd F, Carney D (2000) In: Hansen H (ed) Treatment of NSCLC in Textbook of lung cancer. Martin Dunitz
  2. Pfister D, Johnson D, Azzoli C, et al. (2004) American Society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. JCO 22:330–353View Article
  3. Woo Ey, Yeh H, Chu S, et al. (2002) Cutting edge; regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272–4276PubMed
  4. Hege K, Carbone D (2003) Lung cancer vaccines and gene therapy. Lung Cancer 41:S103–S113View ArticlePubMed
  5. Autexier C (1999) Telomerase as a possible target for anticancer therapy. Chem Biol 6:R299–R303View ArticlePubMed
  6. Fujita Y, Fujikane T, Fujiuchi, et al. (2003) The diagnostic and prognostic relevance of Human Telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma. Cancer 298:1008–1013View Article
  7. Vonderheide RH, Hahn WC, Schultze JL, et al. (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673–679View ArticlePubMed
  8. Minev B, Hipp J, Firat H, et al. (2000) Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97:4796–4801View ArticlePubMed
  9. Vonderheide RH, Anderson KS, Hahn WC, et al. (2001) Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 7:3343–3348PubMed
  10. Arai J, Yasukawa M, Ohminami H, et al. (2001) Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97:2903–2907View ArticlePubMed
  11. Hernandez J, Garcia-Pons F, Lone YC, et al. (2002) Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 99:12275–12280View ArticlePubMed
  12. Scardino A, Gross DA, Alves P, et al. (2002) HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900–5906PubMed
  13. Gross DA, Graff-Dubois S, Opolon P, et al. (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425–433View ArticlePubMed
  14. Schroers R, Huang XF, Hammer J, et al. (2002) Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 62:2600–2605PubMed
  15. Schroers R, Shen L, Rollins L, et al. (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9:4743–4755PubMed
  16. Uchida N, Otsuka T, Shigematsu H, et al. (1999) Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk Res 23:1127–1132View ArticlePubMed
  17. Tahara H, Yasui W, Tahara E, et al. (1999) Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18:1561–1567View ArticlePubMed
  18. Gjertsen MK, Buanes T, Rossland AR, et al. (2001) Intradermal RAS peptide vaccination with granulocyte-macrophage colony-stimulation factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441–450View ArticlePubMed
  19. Vonderheide RH, Domchek SM, Schultze JL, et al. (2004) Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10:828–839View ArticlePubMed
  20. Ostrand-Rosenberg S (2005) CD4+ lymphocytes: a critical component of antitumor immunity. Cancer Invest 23:413–419View ArticlePubMed
  21. Mountain C, Dresler C (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718–1723PubMedView Article
  22. Gjertsen MK, Saeterdal I, Saeboe-Larssen S, Gaudernack G (2003) HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. J Mol Med 81:43–50PubMed
  23. Testa NG, Molineux G (1993) Haematopoiesis: A practical approach, Volume 1, and First Edition. Oxford University Press, Oxford
  24. Sutherland HJ, Eaves CJ, et al. (1991) Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 3:666–672
  25. Pettengell R, Luft T, et al. (1994) Direct comparison by limiting dilution analysis of long-term culture initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 11:3653–3859
  26. Rusten LS, Jacobsen SE, et al. (1994) Functional differences between CD38- and DR-subfractions of CD34+ bone marrow cells. Blood 84:1473–1481PubMed
  27. Danet-Desnoyers GA, Luongo JL, Bonnet DA, Domcheck SM, Vonderheide RH (2005) Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp Hematol 33:1275–1280View ArticlePubMed
  28. Sorensen JB, Hansen HH, Hansen M, et al. (1988) Brain metastasis in adenocarcinoma of the lung; frequency, risk groups, and prognosis. J Clin Oncol 6:1479–1480
  29. Cibotti R, Kanellopoulos JM, Cabaniols J-P, et al. (1992) Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Nati Acad Sci USA 89:416–420View Article
  30. Gross DA, Graff-Dubois S, Opolon P, et al. (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425–433View ArticlePubMed
  31. Parkhurst M, Riley J, et al. (2004) Immunization of patients with hTERT: 540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing Telomerase. Clin Cancer Res 10:4688–4698View ArticlePubMed
  32. Abstr. # 3IN http://​www.​ex2.​excerptamedica.​com/​ciw-04esmo/​
  33. Hirschowitz E, Foody T, Yanelli J, et al. (2004) Autologous dendritic cell vaccines for non-small cell lung cancer. JCO 22:2808–2815View Article
Metadata
Title
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Authors
Paal F. Brunsvig
Steinar Aamdal
Marianne K. Gjertsen
Gunnar Kvalheim
Carrie J. Markowski-Grimsrud
Ingunn Sve
Marianne Dyrhaug
Sissel Trachsel
Mona Møller
Jon A. Eriksen
Gustav Gaudernack
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0145-7

Other articles of this Issue 12/2006

Cancer Immunology, Immunotherapy 12/2006 Go to the issue

Original Article

Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo

Original Article

Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer

Original Article

Increased liver temperature efficiently augments human cellular immune response: T-cell activation and possible monocyte translocation

Original Article

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

Original Article

Macrophage inflammatory protein (MIP)1α and MIP1β differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy

Original Article

Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits